Maria R Roche

Suggest Changes
Learn More
PURPOSE Angiogenesis is important for epithelial ovarian cancer (EOC) growth, and blocking angiogenesis can lead to EOC regression. Cediranib is an oral tyrosine kinase inhibitor (TKI) of vascular(More)
5005 Background: Recurrent ovarian cancer following treatment of advanced disease with platinum-based therapy, such as GC, is associated with poor prognosis and 5-year survival. Addition of iniparib(More)
5028 Background: Olaparib is an orally-bioavailable PARP inhibitor with activity as monotherapy in ovarian and breast cancer; cediranib is a multitargeted kinase inhibitor of VEGFR-1/2/3 and c-kit.(More)
5008 Background: A phase III trial (GOG172) demonstrated improved survival for patients with newly diagnosed and optimally debulked ovarian cancer treated with intraperitoneal (ip) cisplatin and(More)
  • 1